New tumour necrosis factor inhibitors for rheumatoid arthritis: are there benefits from extending choice? [electronic resource]
Producer: 20090624Description: 767-9 p. digitalISSN:- 1468-2060
- Anti-Inflammatory Agents -- economics
- Antibodies, Monoclonal -- economics
- Antibodies, Monoclonal, Humanized
- Arthritis, Rheumatoid -- drug therapy
- Certolizumab Pegol
- Cost-Benefit Analysis
- Humans
- Immunoglobulin Fab Fragments -- economics
- Patient Selection
- Polyethylene Glycols -- economics
- Randomized Controlled Trials as Topic
- Treatment Outcome
- Tumor Necrosis Factor-alpha -- antagonists & inhibitors
No physical items for this record
Publication Type: Editorial; Comment
There are no comments on this title.
Log in to your account to post a comment.